Jacob Borrajo
Directeur Général chez Amber Bio, Inc.
Profil
Jacob Borrajo is the founder of Coral Genomics, Inc. Mr. Borrajo is also the founder of Amber Bio, Inc.
Postes actifs de Jacob Borrajo
| Sociétés | Poste | Début |
|---|---|---|
Amber Bio, Inc.
 Amber Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Amber Bio, Inc. is a biotechnology company based in an undisclosed location. The American company is focused on developing a first-of-its-kind RNA editing platform that can correct genetic mutations in a safe and reversible way. Amber Bio is pioneering new gene editing modalities using multi-kilobase RNA writing to reach previously undruggable diseases. Co-founders Jacob Borrajo and Basem Al-Shayeb received their Ph.D. at leading institutions for gene editing research: Broad Institute of MIT & Harvard and University of California. Jacob Borrajo has been the CEO since incorporation. | Directeur Général | - |
Anciens postes connus de Jacob Borrajo
| Sociétés | Poste | Fin |
|---|---|---|
Coral Genomics, Inc.
 Coral Genomics, Inc. Pharmaceuticals: MajorHealth Technology Coral Genomics, Inc. operates as a biotechnology company that optimizes drug development and deployment by utilizing genomic data from patients. The company was founded by Jacob Borrajo and Atray Dixit in 2018 and is headquartered in San Francisco, CA. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Coral Genomics, Inc.
Coral Genomics, Inc. Pharmaceuticals: MajorHealth Technology Coral Genomics, Inc. operates as a biotechnology company that optimizes drug development and deployment by utilizing genomic data from patients. The company was founded by Jacob Borrajo and Atray Dixit in 2018 and is headquartered in San Francisco, CA. | Health Technology |
Amber Bio, Inc.
Amber Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Amber Bio, Inc. is a biotechnology company based in an undisclosed location. The American company is focused on developing a first-of-its-kind RNA editing platform that can correct genetic mutations in a safe and reversible way. Amber Bio is pioneering new gene editing modalities using multi-kilobase RNA writing to reach previously undruggable diseases. Co-founders Jacob Borrajo and Basem Al-Shayeb received their Ph.D. at leading institutions for gene editing research: Broad Institute of MIT & Harvard and University of California. Jacob Borrajo has been the CEO since incorporation. | Commercial Services |
